FDA WARNING_LETTER - FluxxLab LLC - August 04, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On August 4, 2022, the FDA and FTC issued a Warning Letter to FluxxLab LLC and Arendis, LLC, specifically addressing Arend John Kuijvenhoven, regarding the sale of unapproved and misbranded products related to COVID-19. The FDA reviewed the website fluxxlab.com on July 12, 2022, and August 1, 2022, identifying "Covid-19 Immune Support Tincture" and "CBDA+CBD Oil Tincture" products.
These products are marketed with claims to mitigate, prevent, treat, diagnose, or cure COVID-19, rendering them unapproved new drugs under section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and misbranded drugs under section 502 (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)).
Examples of violative claims include statements about CBDA binding to SARS-CoV-2 spike proteins to prevent infection, found on product pages like "https://fluxxlab.com/product-category/cbda/" and "https://fluxxlab.com/product/
ID · 103ef140-381a-48cd-a9ff-b82a862afe53
Full citation text and observation details available on the Dashboard.